ClinicalTrials.gg
CompletedNCT00333125Updated Nov 18, 2016

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav) and Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt) in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
319
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.

Enrollment
6th of 39
319 · median 89
Started
2006
with 2 others
Phase 3
12 of 42
none open now
Registered
10th of 42
by date
Lead sponsor
27 of 42
Alcon Research

Among the 42 studies testing travoprost in Glaucoma, this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2006, is one of 12 in phase 3, and was the 10th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing travoprost in Glaucoma as a file.
02

Study summary

The purpose of this study is to compare the intraocular pressure (IOP)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 or older.
  • Diagnosis of glaucoma or ocular hypertension.
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Under 18.
  • Other protocol-defined exclusion criteria may apply.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
319 participants (actual)

Study arms

  • Experimental
    Travoprost/Timolol

    Drug: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav) · Other: Timolol Vehicle

  • Active comparator
    Dorzolamide/Timolol

    Drug: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)

Interventions

  • DrugTravoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)

    Drug page: Travoprost

    One drop in the study eye(s) once daily, 9 PM, for 6 weeks

    Also known as: DuoTrav

  • DrugDorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)

    Drug page: Dorzolamide-timolol combination

    One drop in the study eye(s) twice daily for 6 weeks

    Also known as: Cosopt

  • OtherTimolol Vehicle

    One drop in the study eye(s) once daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Mean Intra-Ocular Pressure (IOP)

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Saeed M, Kadir S, Kaufman SL, Murray RR, Milligan F, Cotton PB. Bleeding following endoscopic sphincterotomy: angiographic management by transcatheter embolization. Gastrointest Endosc. 1989 Jul-Aug;35(4):300-3. doi: 10.1016/s0016-5107(89)72796-6. PubMed 2788589 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2006
First posted
Jun 2, 2006
Start
Apr 2006
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00333125
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Jun 2, 2006
Start date
Apr 2006
Primary completion
Feb 2007
Completion
Feb 2007
Last update
Nov 18, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion